MAPK1 and neoplasm: The optimal concentrations (10 μM) of different inhibitors used for our experiments, including SB203580 (p38 inhibitor) and U0126 (ERK1/2 inhibitor), were selected based on their toxic effects on tumor cell viability and proliferation.